Olaf Schickling
About Olaf Schickling
Olaf Schickling is the EU QPPV and Senior Director at BeiGene, with over two decades of experience in pharmacovigilance and clinical research.
Current Role at BeiGene
Olaf Schickling holds the position of EU QPPV, Senior Director at BeiGene, located in the Frankfurt Rhine-Main Metropolitan Area. His responsibilities include overseeing pharmacovigilance activities and ensuring compliance with regulatory requirements within the European Union. His role is critical in maintaining the safety and efficacy of BeiGene's medicinal products.
Previous Experience at BioNTech SE
From 2021 to 2022, Olaf Schickling worked as the Senior Director PV and Risk Management at BioNTech SE. During his tenure, he was involved in pharmacovigilance and risk management activities during a pivotal time for the company in Mainz, Rhineland-Palatinate, Germany. His responsibilities included monitoring drug safety and managing potential risks associated with BioNTech’s pharmaceutical products.
Experience at Mundipharma
Olaf Schickling served as EU-QPPV at Mundipharma from 2020 to 2021 in the Frankfurt Am Main Area, Germany. In this role, he was responsible for pharmacovigilance operations and ensuring adherence to regulatory conditions within the European Union. His work contributed to the safety monitoring of Mundipharma’s product portfolio.
Academic Background in Biology
Olaf Schickling has a robust academic background in Biology. He studied Biology at Heidelberg University, where he earned his first Doctor of Philosophy from 1998 to 2002. Concurrently, he also achieved a Doctorate from the University of Chicago from 1999 to 2002. Prior to that, he studied Biology at Heidelberg University from 1995 to 1998 and at Goethe University from 1993 to 1995.
Leadership Roles in Pharmacovigilance
With over two decades of experience in the pharmaceutical and clinical research industries, Olaf Schickling has held significant leadership roles in pharmacovigilance. He was the Head of Pharmacovigilance at Merz Pharmaceuticals from 2011 to 2014 and also managed pharmacovigilance operations at PharmaLex GmbH from 2015 to 2019. His roles entailed overseeing drug safety, regulatory compliance, and risk management activities, showcasing his expertise in the field.